Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3383100 | Reumatología Clínica | 2012 | 7 Pages |
Abstract
Glucocorticoids, aspirin, conventional antimalarials and immunosuppressants are the mainstay of treatment of Systemic Lupus Erythematosus (SLE). Until recently, the first three were the only agents approved for treatment. A better understanding of the pathophysiology of the immune system has identified new therapeutic targets. In fact, belimumab, a human monoclonal antibody to BLyS inhibitor has become, in recent months, the first drug approved for the treatment of SLE since 1957, underscoring difficulties of all kinds, including economic and organizational ones inherent to clinical trials on this disease. Many other molecules are in various stages of development and soon will have concrete results. In this review, we examined the mechanism of action and most relevant clinical data for these molecules.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Walter A. Sifuentes Giraldo, MarÃa J. GarcÃa Villanueva, Alina L. Boteanu, Ana Lois Iglesias, Antonio C. Zea Mendoza,